Clinical parameters were estimated at the enrollment and at 6 months after.
123 patients with DM-2 that accordingly to the based on evidence clinical judgment, needed injectable treatment for the achievement of good glycemic control were enrolled (insulin 102: glargine 60 / detemir 42 -GLP 1 analog 21: liraglutide 16 / exenatide 5).
The ADDQoL19 (Greek for Greece 19.5.09A from standard UK English rev. 1.3.06) was filled out before and 6 months after commencement of injectable treatment.
Clinical parameters were estimated at the enrollment and at 6 months after.
Frequency of hypoglycemic episodes was estimated with numbers of hypos at the last 2 weeks and severity was evaluated depending on the ability of hypos resolved the patient his own (h.r.o.), resolved with other person assistance but not professional (h.n.prof.ass.) and resolved with professional assistance (h.prof.ass.). Dose adjustment of insulin or GLP -1 analog was done after phone conducts at regular intervals.
•Amori R., Lau J., Pittas A., Efficacy and Safety of Incretin Therapy in •Peyrot M., Rubin R., Khunti K., Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010; 4(Suppl. 1): S11-S18.
1. injectable treatment improves glycemic control, lipids profile and diastolic blood pressure 2. injectable treatment has neutral effect at kidney function, microalbuminuria and systolic blood pressure.
3. injectable treatment deteriorates hypoglycemia, without any difference at the whole number of hypos between insulin and GLP-1 treated patients but with less serious hypos at GLP-1 treated subgroup.
4. injectable treatment does not change anthropometrics at the whole sample but GLP-1 improves and insulin deteriorates BW, WC and BMI and detemir has more neutral effect vs glargine.
5. injectable treatment deteriorates AWI , improves overview item I, has neutral effect at overview item II but further studies are necessary for definite conclusions.
REFERENCES:
•Quality of life: overview item I total sample, glargine sub., detemir sub. GLP -1 sub. p < 0.001 overview item II total sample, glargine sub., detemir sub., GLP -1 sub. p NS AWIS total sample, glargine sub., detemir sub., GLP -1 sub. p < 0.001
•Anthropometrics: BW, WC, BMI total NS, glargine sub. p < 0.05, detemir sub. p NS, GLP-1 sub. p < 0.05).
•Glycemic control: Hba1c total sample 9,49 ± 1,14 (8-12) vs 7,22 ± 0,60 (6.2-10.3) p < 0.001 glargine subgroup 9,33 ± 1,08 (8-12) vs 7,10 ± 0,44 (6, (5) (6) (7) (8) 8) 
GLP -1 vs insulin NS
•Hypoglycemia: All types: total sample, glargine sub., detemir sub. p<0.001, detemir vs glargine h.r.o. p < 0.05, h.n.prof. ass. NS, h.prof, h.n.prof. ass. p <0.05, h.Prof. ass. P < 0.05 
